Invivoscribe在中国向NMPA提交LeukoStrat®CDx FLT3突变检测，并扩大公司规模，在上海增加实验室，为合作伙伴提供全面支持。marketing2022-01-03T02:51:34+00:00May 12th, 2020|2020 Press Releases, Press Releases| 更多详细信息
Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatmentmarketing2021-02-15T19:48:14+00:00May 6th, 2020|2020 Publications, Publications| 更多详细信息
Upgraded Standardized Minimal Residual Disease Detection by Next-Generation Sequencing in Multiple Myelomamarketing2021-02-11T21:50:38+00:00May 1st, 2020|2020 Publications, Publications| 更多详细信息
Primary non-Hodgkin lymphoma of the tongue base: the clinicopathology of seven cases and evaluation of HPV and EBV statusmarketing2021-02-11T21:53:32+00:00April 1st, 2020|2020 Publications, Publications| 更多详细信息
Quantitation of CMV Specific T-Cell Expansion Using T Cell Receptor Beta Locus Deep Sequencing to Identify Patients at Risk of Viral Complicationsmarketing2021-02-11T21:56:18+00:00March 1st, 2020|2020 Publications, Publications| 更多详细信息
Clinical Utility of NGS in Lymphoid Malignanciesmarketing2021-02-23T01:10:44+00:00February 27th, 2020|2020 Videos, Videos, Webinars| 更多详细信息
Molecular profiling of immunoglobulin heavy-chain gene rearrangements unveils new potential prognostic markers for multiple myeloma patientsmarketing2021-02-11T21:58:45+00:00February 6th, 2020|2020 Publications, Publications| 更多详细信息
Monitoring minimal residual disease in the bone marrow using next generation sequencingmarketing2021-02-11T22:00:56+00:00January 17th, 2020|2020 Publications, Publications| 更多详细信息
欧盟委员会批准安斯泰来(Astellas)的XOSPATA，用于经验证试验检测出FLT3突变的复发或难治性急性髓系白血病患者，包括Invivoscribe LeukoStrat CDx FLT3突变检测试剂盒marketing2022-01-03T02:51:42+00:00December 5th, 2019|2019 Press Releases, Press Releases| 更多详细信息
Plasma Cell Myeloma Residual Disease Quantitation Using a Next-Generation Sequencing-Based IGH Clonal Rearrangement Assay with the Aid of a “Spike-in” Clonal Sequencemarketing2021-02-11T23:36:10+00:00November 13th, 2019|2019 Publications, Publications| 更多详细信息
